Lianhua Qingke ameliorates lipopolysaccharide‐induced lung injury by inhibiting neutrophil extracellular traps formation and pyroptosis

LHQK is a patented Traditional Chinese Medicine (TCM) which is clinically used for acute tracheobronchitis, cough, and other respiratory diseases. Recent studies have proved that LHQK exhibits excellent clinical efficacy in the treatment of acute lung injury (ALI). However, the corresponding mechanisms remain largely unexplored. In this study, we investigated the effects and the underlying mechanisms of LHQK on lipopolysaccharide (LPS)‐induced ALI in mice. The pathological examination, inflammatory cytokines assessments, and mucus secretion evaluation indicated that administration of LHQK ameliorated LPS‐induced lung injury, and suppressed the secretion of Muc5AC and pro‐inflammatory cytokines (IL‐6, TNF‐α, and IL‐1β) in plasma and BALF. Furthermore, the results of cell‐free DNA level showed that LHQK significantly inhibited LPS‐induced NETs formation. Western blot revealed that LHQK effectively inhibited LPS‐triggered pyroptosis in the lung. In addition, RNA‐Seq data analysis, relatively bioinformatic analysis, and network pharmacology analysis revealed that LHQK and relative components may play multiple protective functions in LPS‐induced ALI/acute respiratory distress syndrome (ARDS) by regulating multiple targets directly or indirectly related to NETs and pyroptosis. In conclusion, LHQK can effectively attenuate lung injury and reduce lung inflammation by inhibiting LPS‐induced NETs formation and pyroptosis, which may be regulated directly or indirectly by active compounds of LHQK.